SELEKTİF ESTROJEN RESEPTÖR MODÜLATÖRÜ OLAN BAZEDOKSİFENİN RAT MODELİNDE OLUŞTURULAN ENDOMETRİOZİS TEDAVİSİNDEKİ ROLÜ

Abstract

Aim: The only factor that is proved on the pathogenesis of endometriosis is estrogen. The aim of this study is to investigate the effect of bazedoxifene, a third generation selective estrogen receptor modulator, on the endometriotic implants in the rat endometriosis model by using histopathological examination and immunohistochemical assays. Materials and Method: This randomized, placebocontrolled, experimental study was conducted in the Animal Research Laboratory at Ankara Education and Research Hospital. The study was performed on 20 Wistar female albino rats. Experimental endometriosis model was constituted with implantation of autologous endometrial tissue on the right side of the pelvic wall. The endometriotic implants were examined by second laparatomy after 30 days, and the rats were divided randomly into two groups. Group 1 received 3 mg/ kg Bazedoxifene (n =10) per oral, once a day, for 30 more days. Group 2 (n =10) was the control group and did not receive any medical treatment. After 30 days of treatment period, the third laparatomy was performed, endometriotic lesions volumes were measured, and endometriotic foci were extracted for histopatological and immunohistochemical evaluation. Histopathological scoring was evaluated according to preservation of epithelial layer. In addition, endometrial implants were evaluated immunohistochemically for VEGF, MMP-2 and MMP-9. Results: The volumes of the lesions were smaller in the group which was treated with bazedoxifene than the ones in the control group which was statistically significant (p 0.05). Conclusion: Bazedoxifene treatment was seen to have a regressive effect on the volumes and histopathological structure of endometriotic implants. Bazedoxifene could be regarded as a new alternative in the treatment of endometriosis.